Provided by Tiger Trade Technology Pte. Ltd.

Roivant Sciences Ltd.

36.30
-0.5400-1.47%
Post-market: 36.360.0600+0.17%19:51 EDT
Volume:6.19M
Turnover:225.49M
Market Cap:26.22B
PE:-77.23
High:37.18
Open:37.03
Low:36.23
Close:36.84
52wk High:37.97
52wk Low:11.60
Shares:722.41M
Float Shares:581.00M
Volume Ratio:1.12
T/O Rate:1.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4700
EPS(LYR):-0.5400
ROE:-8.52%
ROA:-16.48%
PB:6.20
PE(LYR):-67.22

Loading ...

Immunovant director Robert Graham Susman sells 2,502 shares for $67,988.34

Reuters
·
May 02

Zura Bio names Marlyn Mathew principal financial, accounting officer after CFO exit

Reuters
·
Apr 24

Roivant CEO Matthew Gline disposes of 289,774 common shares for $8.45 million

Reuters
·
Apr 21

Roivant Sciences (ROIV) Gets a Buy from J.P. Morgan

TIPRANKS
·
Apr 18

Roivant Sciences Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Apr 17

Roivant Sciences Ltd : Piper Sandler Raises Target Price to $40 From $22

THOMSON REUTERS
·
Apr 16

Roivant Chief Accounting Officer Jennifer Humes disposes 13,538 shares for $384,278

Reuters
·
Apr 11

Roivant Sciences price target raised to $34 from $30 at Jefferies

TIPRANKS
·
Apr 07

Roivant Sciences (ROIV) Is Up 6.8% After Mixed Autoimmune Trial Updates - Has The Bull Case Changed?

Simply Wall St.
·
Apr 04

Immunovant CEO Eric Venker disposes of common shares worth $8.5 million

Reuters
·
Apr 04

Ro says working with Eli Lilly to launch Zepbound KwikPen

TIPRANKS
·
Apr 03

BRIEF-Ro Says Working With Eli Lilly To Launch Zepbound Kwikpen Nationwide On Its Platform

Reuters
·
Apr 03

Immunovant says Phase 3 batoclimab trials miss primary endpoint in thyroid eye disease

Reuters
·
Apr 02

Roivant’s Priovant starts Phase 2b/3 brepocitinib trial in lichen planopilaris

Reuters
·
Apr 02

Roivant Sciences Ltd - Phase 3 Studies of Batoclimab in Ted Fail to Meet Primary Endpoint

THOMSON REUTERS
·
Apr 02

Roivant Sciences Ltd: Topline Phase 3 Data in Niu and Phase 3 Study Initiation in Cs Are Expected in Second Half of Calendar Year 2026

THOMSON REUTERS
·
Apr 02

Roivant Announces Expansion of Brepocitinib Development Program With New Phase 2B/3 Trial in Lichen Planopilaris (Lpp) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (Ted)

THOMSON REUTERS
·
Apr 02

Roivant Sciences Ltd - Ted Study Patients Show Greater Proptosis Improvement After High-Dose Period

THOMSON REUTERS
·
Apr 02

Roivant director Meghan FitzGerald disposes of common shares worth $1.92 million

Reuters
·
Mar 31

S&P 500 Futures Climb In Premarket Trading; United Therapeutics, Alcoa Lead

Dow Jones
·
Mar 30